Melissa L. Geddie
Biogen (United States)(US)C4 Therapeutics (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Parkinson's Disease Mechanisms and Treatments, Glycosylation and Glycoproteins Research, Liver physiology and pathology, Axon Guidance and Neuronal Signaling
Most-Cited Works
- → α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity(2009)533 cited
- → Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity(2009)292 cited
- → Polyamine pathway contributes to the pathogenesis of Parkinson disease(2010)157 cited
- → A novel screening method to assess developability of antibody-like molecules(2015)76 cited
- → Rapid Evolution of β-Glucuronidase Specificity by Saturation Mutagenesis of an Active Site Loop(2004)70 cited
- → A Comparison of Directed Evolution Approaches Using the β-Glucuronidase Model System(2003)63 cited
- → Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models(2019)59 cited
- → MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM(2019)31 cited
- → Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting(2016)28 cited
- → Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle(2014)28 cited